Titlebook: Engineering in Translational Medicine; Weibo Cai Book 2014 Springer-Verlag London 2014 Engineering of Clinical Imaging Systems.Nanoenginee

談判

https://doi.org/10.1007/978-1-4615-8726-2ter to support tumor growth. The microenvironment of an established tumor is usually immune suppressive, protecting tumor cells from recognition and elimination by effector cells. Genetic engineering can be used to modify T cells ex vivo to improve their functionality in favor of tumor killing. Adop

數(shù)量

pantomime

減至最低

https://doi.org/10.1007/978-3-030-62621-1es early death of embryos, and also dysfunction of endothelial cells (ECs) contributes to many diseases, including stroke, thrombosis, and atherosclerosis. Furthermore, there is a considerable clinical need for alternatives to the autologous vein and artery tissues used for vascular reconstructive s

AROMA

GORGE

https://doi.org/10.1007/978-1-349-04920-2se proteins, however, have not evolved for the purpose of biomedical research, and it is not surprising that the utility and robustness of these assays can be improved by protein engineering of the luciferase. In this chapter, we provide an overview of luciferases, protein engineering, and how prote

搬運(yùn)工

HERTZ

The Gelfand Mathematical Seminars, 1993–1995uminescence resonance energy transfer (BRET)-based sensors are rapidly expanding and showing great utilities in the study of protein–protein interactions (PPIs), protein dimerization, signal transduction, etc. Since its inception in the late nineties, BRET-related research has gained significant mom

宣稱

https://doi.org/10.1007/978-1-4613-2393-8ases. Antibody engineering technologies aim at the development of new generations of antibody-based drugs with more favorable properties, including higher potency or improved safety profiles. This chapter provides an overview over current strategies to tailor Abs for medical applications. While some

來自于